Literature DB >> 8847141

Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements.

T Okado1, R G Hawley.   

Abstract

In previous work, we reported the development of the B9/BMI syngeneic murine bone marrow metastasis model. Interleukin (IL)-6-dependent, IL-I-producing B9/BMI cells, which preferentially home to and colonise the vertebral and femoral marrow after i.v. injection, exhibit striking similarity in cell surface phenotype to human myeloma cells, especially the expression of 3 adhesion molecules, CD44, VLA-4 and ICAM-I. Because the haematopoietic microenvironment consists of different cell types, such as endothelial cells, fibroblasts, adipocytes and macrophages, we investigated the functional significance of these adhesion molecules in heterotypic binding assays between B9/BMI cells and a newly established bone marrow-derived endothelial cell line (BMEC), a fibroblastoid pre-adipocyte cell line (BMS2.2) and primary bone marrow-derived macrophages. B9/BMI cells adhered well to all stromal elements: a combination of monoclonal antibodies (MAbs) against CD44 and VLA-4 significantly inhibited the adherence of B9/BMI cells to BMEC and BMS2.2 cells, whereas binding of B9/BMI cells to macrophages was partially blocked with an anti-ICAM-I MAb. Our results implicate multiple recognition mechanisms, including those involving CD44, VLA-4 and ICAM-I, in the retention of B9/BMI cells in the bone marrow.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8847141     DOI: 10.1002/ijc.2910630613

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Significance of VLA-4-VCAM-1 interaction and CD44 for transendothelial invasion in a bone marrow metastatic myeloma model.

Authors:  T Okada; R G Hawley; M Kodaka; H Okuno
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

Review 2.  Bone disease in multiple myeloma.

Authors:  Øyvind Hjertner; Therese Standal; Magne Børset; Anders Sundan; Anders Waage
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 3.  Crossing the endothelial barrier during metastasis.

Authors:  Nicolas Reymond; Bárbara Borda d'Água; Anne J Ridley
Journal:  Nat Rev Cancer       Date:  2013-12       Impact factor: 60.716

Review 4.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

5.  Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.

Authors:  T Yoneda; A Sasaki; C Dunstan; P J Williams; F Bauss; Y A De Clerck; G R Mundy
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

6.  High-content adhesion assay to address limited cell samples.

Authors:  Jay W Warrick; Edmond W K Young; Eric G Schmuck; Kurt W Saupe; David J Beebe
Journal:  Integr Biol (Camb)       Date:  2013-02-21       Impact factor: 2.192

7.  Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells.

Authors:  Tomoko Okada; Shingo Akikusa; Hiroaki Okuno; Masato Kodaka
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

8.  The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells.

Authors:  Qun Zhou; Yuan Yao; Solveig G Ericson
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

Review 9.  Stepping out of the flow: capillary extravasation in cancer metastasis.

Authors:  Fayth L Miles; Freddie L Pruitt; Kenneth L van Golen; Carlton R Cooper
Journal:  Clin Exp Metastasis       Date:  2007-09-29       Impact factor: 5.150

10.  Extraosseous (extramedullary) plasmacytomas: a clinicopathologic and immunophenotypic study of 32 Chinese cases.

Authors:  Zhuo Zuo; Yuan Tang; Cheng-Feng Bi; Wen-Yan Zhang; Sha Zhao; Xiao-Qing Wang; Qun-Pei Yang; Li-Qun Zou; Wei-Ping Liu
Journal:  Diagn Pathol       Date:  2011-12-19       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.